Marvel Biosciences announced that its lead drug candidate, MB-204, demonstrated significant improvements in behavioral and cognitive functions in a Fragile X mouse model during preclinical trials. The drug showed dose-dependent efficacy and durable effects even after treatment stopped, supporting its potential for treating Fragile X syndrome and other autism spectrum disorders. These results add to previous positive findings in Rett syndrome and other ASD models, strengthening the case for advancing MB-204 to clinical trials. The company is also awaiting results from another related preclinical study.
Marvell Technology posted a record Q2 revenue of $2.74 billion, driven by broad growth in data center products and customers. The company raised its revenue guidance for fiscal years 2027 and 2028, supported by strong demand for AI connectivity, cust...
Marvel Biosciences Corp. has received approval from the TSX Venture Exchange to extend the closing deadline for its private placement from August 31 to September 14, 2026. The company, which develops synthetic chemical derivatives of off-patent drugs...
Marvell Technology has delivered a 242% gain over the past year and is expected to continue growing due to accelerating AI infrastructure spending and custom silicon revenue set to more than double in fiscal 2028. The company reported strong Q2 fisca...
Marvell Technology and Broadcom both reported strong AI-driven revenue growth, but at vastly different scales. Broadcom's AI chip revenue hit $16.7 billion, part of its $29.6 billion total, while Marvell's entire business was $2.7 billion. Marvell fo...
Marvell Technology's CEO Matt Murphy attributes the company's 241% stock rise over the past year to a decade-long build of trust with major tech firms. This trust has enabled Marvell to secure significant AI ecosystem partnerships, including deals wi...
